Stallion India Fluorochemicals Investor Presentation: Financial Results & Expansion Plans
Stallion India Fluorochemicals presented its Q4 FY26 results and expansion plans. Key highlights include a 10,000 MT R-32 manufacturing facility in Bhilwara, Rajasthan, with expected commissioning in October 2026 and a topline potential of ₹250 crore in FY26-27. The company is also expanding into high-purity helium and specialty gases, aiming for a 30-35% CAGR over the next three years.
The information pertains to major strategic initiatives, capacity expansions, and financial projections, which are likely to have a substantial impact on the company's future performance and investor perception.
The announcement details significant expansion plans, new facility approvals, and a positive financial outlook, indicating strong growth prospects for the company.
Stallion India Fluorochemicals Limited has released its Investor Presentation detailing the financial results for the Quarter and Financial Year ended 31st March, 2026. The presentation outlines the company's strategic vision for growth, including forward integration and expansion into specialty and semiconductor gas capabilities at its Khalapur facility. The company is investing in liquid helium processing capacity of 1,200 metric tons per annum and has received Environmental Clearance (EC) for a proposed 10,000 MT R-32 manufacturing facility at Bhilwara, Rajasthan. This facility is expected to commence construction in 2027 and will benefit from incentives under the Rajasthan Investment Promotion Scheme (RIPS) 2024. Strategic expansion into next-generation HFO manufacturing and high-purity helium, supported by global sourcing partnerships, is also underway, with initiatives expected to improve profit margins by 3-4%. The company also provided a financial outlook, expecting to grow at a 30-35% CAGR for the next three years while maintaining sustainable margins. The R-32 manufacturing facility in Bhilwara is targeted for completion in approximately 8 months, with expected commissioning in October 2026, projecting a topline potential of ₹250 crore in FY26-27 and ₹500-600 crore in FY27-28, with an expected PAT margin of 22-24%.
What to do with a filing like this
Stallion India Fluorochemicals Limited filed this with the NSE as a statutory disclosure, categorised under investor presentation. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Stallion India Fluorochemicals Limited. Read the original for the full detail.